Recce Pharmaceuticals Secures $57.5M in Series B Funding to Revolutionize Synthetic Antibiotics Against Superbugs

Recce Pharmaceuticals Ltd has reached a major milestone by raising US$57,500,000 in its latest funding round—a clear vote of confidence in its groundbreaking approach to combating antibiotic resistance. As a pioneering biopharmaceutical company, Recce is at the forefront of developing a new class of synthetic antibiotics designed to address the global health crisis posed by superbugs. Its patented lead candidate, RECCE®327, is specifically engineered to treat blood infections and sepsis caused by dangerous bacteria such as E. coli and S. aureus, including their resistant, superbug forms. Over recent years, pre-clinical testing in both laboratories and animal models, conducted in Australia and abroad, has yielded highly promising results, reinforcing the potential of its innovative therapeutic approach. The newly acquired funds will be strategically deployed to advance the development and commercialization of RECCE®327 through several pivotal initiatives. Investments will enhance manufacturing capabilities at its Australian facilities, focus on expanding preclinical research programs, and support the meticulous regulatory preparations required for the upcoming first-in-human clinical trials. Additionally, the capital will bolster collaborations with established clinical research partners in the USA, ensuring that the development process is both robust and internationally harmonized. This infusion of resources not only accelerates Recce Pharmaceuticals’ pathway toward transforming patient outcomes but also reinforces its commitment to mitigating one of the most urgent challenges in global health. With a proven automated manufacturing process already in place, the company is well-positioned to transition from promising preclinical success to groundbreaking clinical advances in the fight against antibiotic-resistant infections.